1	
2	Testing effectiveness and implementation of a standardized approach to sexual dysfunction
3	screening among adolescent and young adult-aged survivors of childhood cancer: A type I
4	hybrid, mixed methods trial protocol
5	
6	Effectiveness of sexual dysfunction screening among AYA cancer survivors: a study protocol
7	
8	Jenna Demedis MD MS <sup>1,2</sup> , Julia Reedy MA <sup>3</sup> , Kristen Miller MS <sup>1</sup> , Junxiao Hu, PhD <sup>1</sup> , James L.
9	Klosky PhD ABPP <sup>4,5</sup> , Brooke Dorsey Holliman PhD <sup>3,6</sup> , Pamela N. Peterson MD MPH <sup>7,8</sup> , Eric J.
10	Chow MD MPH <sup>9</sup> , Christina Studts PhD, MSPH, LCSW <sup>1,3</sup>
11	
12 13	<sup>1</sup> Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
14 15	<sup>2</sup> Center for Cancer and Blood Disorders at Children's Hospital Colorado, Aurora, CO, USA
16 17 18	<sup>3</sup> Adult & Child Center for Health Outcomes Research & Delivery Science (ACCORDS), University of Colorado School of Medicine, Aurora, CO, USA
19 20 21	<sup>4</sup> Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta, Atlanta, GA, USA figure
21 22 23	<sup>5</sup> Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
23 24 25	<sup>6</sup> Department of Family Medicine, University of Colorado School of Medicine, Colorado, USA
26 27	<sup>7</sup> Department of Internal Medicine, University of Colorado School of Medicine, Colorado, USA
28 29	<sup>8</sup> Denver Health Medical Center, Denver, Colorado, USA
30 31 32	<sup>9</sup> Clinical Research and Public Health Sciences Divisions, Fred Hutchinson Cancer Center, Washington, USA
33	
34	*Corresponding author
35	Email: Jenna.Demedis@childrenscolorado.org (JD)
36	

#### 37 Abstract

38 Background: Approximately 20-50% of adolescent and young adult-aged childhood cancer survivors (AYA-CCS) experience sexual dysfunction (SD), although this healthcare need is 39 widely underrecognized. Previous research from both AYA-CCS patients and their providers 40 41 report that SD needs are unaddressed despite patient desires for SD discussions to be incorporated as part of their care. Patients and providers agree that standardized use of a 42 patient-reported outcome measure may facilitate SD discussions; an SD screening approach 43 was developed with patient and provider input. This study will measure the effectiveness of a 44 45 standardized SD screening intervention and assess implementation outcomes and multilevel 46 barriers and facilitators to guide future research. 47 Methods: This multi-site, mixed methods, type 1 effectiveness-implementation hybrid trial will be 48 evaluated using a pre-post design (NCT05524610). The trial will enroll 86 AYA-CCS (ages 15-49 50 39) from two cancer centers in the United States. The SD intervention consists of core 51 fundamental functions with a "menu" of intervention options to allow for flexibility in delivery and 52 tailoring in variable contexts. Effectiveness of the intervention on facilitating SD communication 53 will be measured through patient surveys and clinical data; multivariable logistic regression will 54 be used for the binary outcome of self-reported SD screening, controlling for patient-level

predictors. Implementation outcomes will be assessed using mixed methods (electronic health
record abstraction, patient and provider surveys, and provider interviews. Quantitative and
qualitative findings will be merged using a joint display to understand factors affecting
intervention success.

59

Implications: Identification and treatment of SD in AYA-CCS is an important and challenging
 quality of life concern. The type 1 hybrid design will facilitate rapid translation from research to
 practice by testing the effects of the intervention while simultaneously identifying multilevel

barriers and facilitators to real-world implementation. This approach will inform future testing
 and dissemination of the SD screening intervention.

65

#### 66 Introduction

67 Sexual dysfunction (SD) is estimated to occur in 20-50% of adolescent and young adultaged childhood cancer survivors (AYA-CCS) but is widely underrecognized [1-8]. SD 68 encompasses lack of desire for sex, arousal difficulties (erection, lubrication), inability to achieve 69 70 climax/ejaculation, anxiety about sexual performance, climaxing/ejaculating too rapidly, physical 71 pain during intercourse, and lack of pleasure [9]. In AYA-CCS, SD may occur as a result of 72 physiologic and psychosexual reasons, and while certain treatment factors (e.g., cranial or 73 pelvic irradiation, central nervous system tumors, chemotherapy) exist, demographic, developmental, psychologic and social factors also contribute [1-8, 10-13]. SD is associated 74 75 with poorer quality of life, including physical, social, and mental health; therefore, providing 76 assessment, education, and counseling for AYA-CCS experiencing SD is critical [1-4, 9-12]. 77 While data are limited in cancer patients of all ages generally, two studies have suggested that 78 addressing SD may improve psychological distress [14, 15]. Because the multidisciplinary 79 pathophysiology of SD in this population makes estimating individual SD risk difficult, all AYA-80 CCS warrant SD-focused education and evaluation.

Despite the prevalence and impact of SD among AYA-CCS, patients largely report that their needs in this area are unaddressed by their primary care providers and oncologists [7, 16-19]. This is consistent with findings from providers, with 50% of pediatric oncologists reporting rarely or never discussing sexual function with their AYA-CCS [20]. Patient- and provider-level barriers are well described, including discomfort, lack of provider knowledge, and lack of patient understanding of how to broach the topic [19, 21-23]. Multiple qualitative studies have demonstrated that patients would like their providers to initiate conversations to address SD

directly, privately and regularly [16, 19, 23]. Further, national guidelines recommend regular
discussions of sexuality and cancer throughout cancer care and follow-up [24-26].

Given the aforementioned barriers, which may be particularly salient in younger 90 populations, our prior research evaluated the utility of using a patient-reported outcome 91 92 measure for SD screening in AYA-CCS followed in pediatric settings (age 15-24 years), eliciting patient and provider perspectives in gualitative interviews [22, 27]. Both groups were in favor of 93 using a patient-reported outcome measure to address barriers and facilitate SD conversations. 94 While no SD screening tools have been specifically validated in the AYA-CCS population, our 95 96 prior research qualitatively evaluated the National Institute of Health-developed Patient-97 Reported Outcomes Measurement Information System (PROMIS®) Sexual Function and Satisfaction (SexFS) Brief v2.0 tool in the AYA-CCS population [27, 28]. The SexFS Brief was 98 found to be acceptable and useful, with demonstrated response process and content validity 99 100 [27]. In addition to evaluating the utility of the SexFS Brief, patients and providers offered 101 perspectives for how the SexFS Brief could be implemented into clinical use, including recommendations for delivery, results storage and review, and needed resources [22, 27]. 102 103 These recommendations were included in an SD screening intervention prototype that is being 104 iteratively adapted in an ongoing phase of research. Once iterative adaptations are completed, 105 the study described here will simultaneously test effectiveness and implementation outcomes of this screening intervention. 106

107 Clinical use of the SexFS Brief has the potential to improve screening and detection of 108 SD among AYA-CCS, which is the first step toward providing SD-related healthcare and 109 ultimately improving related quality of life concerns. However, because SD screening utilizing 110 the SexFS Brief is not yet part of routine care with the AYA-CCS population, and because 111 patient-reported outcomes are not commonly used in this population, additional research is 112 required to evaluate the effectiveness of the screening intervention in facilitating SD 113 communication, as well as its potential for implementation in clinical settings.

114

#### 115 Study Purpose

The purpose of this pilot type 1 hybrid effectiveness-implementation trial is to 1) 116 demonstrate preliminary effectiveness of the standardized SD screening intervention in 117 118 improving SD communication between AYA-CCS (current ages 15-24 years) and their providers, and to 2) assess implementation outcomes and multilevel barriers and facilitators to 119 120 guide future research. Use of a hybrid trial design will facilitate rapid translation from research to 121 practice by addressing implementation, service, and client outcomes [29]. This study will use 122 mixed methods to quantitatively measure effectiveness and implementation outcomes in a large 123 sample while simultaneously contextualizing these outcomes by integrating them with 124 complementary in-depth qualitative data analysis. Quantitative data at the patient and provider levels will be obtained through surveys and from electronic health record (EHR) data. 125 126 Quantitative data will be supplemented with qualitative data collection via concurrent open-127 ended survey questions as well as nested sequential explanatory qualitative interviews with providers. The following quantitative, gualitative, and mixed methods research questions will 128 129 guide the study: 130 Quantitative: 131 Effectiveness: What effects does the SD screening intervention have on patient-reported 132 133 SD communication and patient satisfaction with SD healthcare? What impact does the 134 intervention have on clinical care (e.g., documentation of SD, referral patterns)?

135 *Implementation:* How do patients and providers rate the SD screening intervention's

136 preliminary implementation outcomes (acceptability, appropriateness, feasibility and fidelity)?

137 How often is the intervention utilized by patients and providers?

138

139 <u>Qualitative:</u>

*Effectiveness:* What are providers' impressions of the SD screening interventions'
 effectiveness? What are providers' perceptions of barriers and facilitators affecting the

142 interventions' effectiveness?

*Implementation:* What are the barriers and facilitators to adopting and implementing the
SD screening intervention? How does the intervention fit in a pediatric oncology clinic context?
Are there other contextual factors that affect its use and utility? Are changes to the intervention
needed?

147

148 <u>Mixed Methods:</u>

149 *Effectiveness:* What barriers and facilitators exist that may explain or expand upon

150 effectiveness results, including variability in clinical effects? What changes to the SD screening

151 intervention could improve its effectiveness?

152 *Implementation:* What contextual factors are contributing to the SD screening

153 intervention's implementation outcomes? What changes to the intervention could improve its

reach, acceptability, feasibility, and other implementation/process outcomes?

#### 155 Methods and analysis

#### 156 <u>Study Frameworks</u>

157 The overall structure and outcomes of this study are guided by the implementation

science framework, RE-AIM (Reach, Effectiveness, Adoption, Implementation and

159 Maintenance) [30]. RE-AIM is used to systematically assess multiple outcomes of intervention

implementation, including effectiveness, with the overarching goal of increasing the population

- 161 impact of interventions through widespread adoption, implementation, and maintenance
- reaching all patients who could benefit. In this study, RE-AIM will inform our assessment of
- screening intervention effectiveness, reach, adoption and implementation across settings and
- patient subgroups, as well as its potential for scaling up and spreading to additional settings.

- 165 While RE-AIM will guide planning and evaluation of effectiveness and implementation, the
- updated Consolidated Framework for Implementation Research (CFIR 2.0) will inform
- 167 evaluation of contextual factors, including multilevel barriers and facilitators, that may influence
- 168 RE-AIM domains, informing future intervention adaptation and implementation [30-36]. Use of
- 169 RE-AIM and CFIR 2.0 is further described in the Data Collection section below.
- 170
- 171 <u>Study Design</u>
- 172 A multi-site type 1 effectiveness-implementation hybrid trial design will be used to
- simultaneously establish preliminary effectiveness and implementation outcomes (Table 1;
- 174 Figure 1; S1 Protocol). As a type 1 hybrid trial, the primary objective of this study is to determine
- the effectiveness of the SD screening intervention at improving the occurrence SD-focused
- 176 patient-provider communication. Additional effectiveness and implementation outcomes will be
- 177 secondary/exploratory and are detailed below.
- 178

# Figure 1. Schedule of patient participant enrollment, screening intervention, and assessment.

#### 181 Table 1. Protocol Overview

Data Category	Information	
Primary registry and trial identifying	ClinicalTrials.gov	
number	NCT05524610	
Date of registration in primary registry	2022-09-01	
Secondary identifying numbers	COMIRB 22-0709	
Funding source	NIH K08 CA263192 (PI JD)	
Contact for public and scientific queries	Jenna Demedis, MD, MS	
	Jenna.Demedis@cuanschutz.edu	
Study Locations	Children's Hospital Colorado (USA)	
	Seattle Children's Hospital (USA)	
Title	Development and Evaluation of a Screening Approach for	
	Sexual Dysfunction in Childhood Cancer Survivors	
Intervention	Standardized sexual dysfunction screening using	
	PROMIS SexFS Brief vs. usual care	
Key inclusion and exclusion criteria	AYA-CCS: 15-24 years old; current or prior history of	
	cancer; cancer was diagnosed prior to age 18; received	
	cancer-directed treatment. Patients will be excluded if	
	they are unable to read/speak English; have insufficient	
	cognitive function to complete study measures; are at end	
	of life	

	Medical providers: pediatric oncology physicians, nurse practitioners, physician assistants, registered nurses, and medical assistants at study sites
Study type	Interventional (clinical trial)
Study design	Pilot type 1 hybrid effectiveness-implementation study with pre-post design
Date of first enrollment	2023-02-14
Target sample size	AYA-CCS: Minimum of 86 off-therapy participants (43 pre- and 43 post-intervention) for the primary outcome, with additional on-therapy participants) Medical providers: 16-24 (surveys), 10-15 (interviews)
Recruitment status	Recruiting
Primary outcome	SD screening intervention effectiveness: Comparison of pre- and post- intervention percentage of off-therapy AYA- CCS reporting that his/her provider has communicated with them about sexual function
Key secondary outcomes	SD screening intervention effectiveness across cancer care continuum; patient satisfaction; patient report of needs being met; Intervention reach; provider adoption of intervention; patient-reported acceptability, feasibility, appropriateness; provider-reported acceptability, feasibility, appropriateness; provider-identified barriers; observed intervention fidelity; adaptations

182 AYA-CCS: Adolescent and young-adult aged childhood cancer survivors

183 COMIRB: Colorado Multiple Institutional Review Board

184 NIH: National Institute of Health

185 PI: Principal Investigator

186 PROMIS SexFS Brief: National Institute of Health-developed Patient-Reported Outcomes Measurement

187 Information System (PROMIS®) Sexual Function and Satisfaction (SexFS) Brief v2.0

- 188 SD: Sexual dysfunction
- 189

190 The standardized SD screening intervention will be tested in a pre-post study design in

191 which the SD screening intervention will be implemented with all patients as standard of care;

this is justified by national guidelines recommending universal sexual health conversations for

all age-appropriate oncology patients. Prior to initiating the SD screening intervention, patient

surveys will be used to collect baseline data on SD communication and clinical care.

195 Subsequently, the SD screening intervention will begin. After intervention initiation, quantitative

196 (survey, EHR) and qualitative (interviews, open-ended questions) data will be collected to

197 evaluate effectiveness and implementation outcomes.

198

199 Intervention Design and Implementation Package

200 The standardized SD screening intervention is a multicomponent intervention composed 201 of required components with flexible delivery, tailored to each study site based on a "menu" of 202 options (Table 2). This approach follows the implementation science concept of functions and 203 forms of an intervention: functions are the fundamental purpose or desired effect of the intervention, while forms are the intervention details, modalities, and activities that may vary 204 205 based on contextual factors [37, 38]. The core functions of the SD screening intervention, 206 detailed in Table 2, include (1) routine/standardized SD screening using the SexFS Brief, (2) 207 consistent follow-up and management of screening results, and (3) patient and provider 208 education. These functions address the key barriers driving inadequate SD-focused healthcare: AYA patients' uncertainty about SD risks and ability to address these with the medical team. 209 and clinicians' lack of awareness of SD risks and how to address/manage these. Examples of 210 211 the "forms" that each function may take, such as details of the target population or modality of 212 delivery, are detailed in Table 2. At study initiation, the research team will work with each clinical site to adapt the SD screening intervention to their context, selecting from the "menu" of forms. 213 214 The research team will provide relevant background information from prior phases of research 215 (e.g., patient- and provider-recommendations and preferences) to inform tailoring to each site's 216 unique context, including existing resources, workflows and barriers.

217

218

## Table 2. Core functions and forms of the sexual function screening intervention

PATIENT LEVEL			
MOTIVATING NEED/PROBLEM	CORE FUNCTIONS	FORMS - DECISIONS AND EXAMPLES	
AYA oncology patients are uncertain of sexual dysfunction (SD) risks or ability to address them with their medical team	Patient knowledge of SD risks is increased through education Patients participate in regular written screening for SD concerns using a patient- reported outcome measure (e.g. PROMIS SexFS Brief) Patients are enabled to address SD concerns through increased comfort and privacy	<ol> <li>Patient Education - Examples:         <ul> <li>Primary team educates patients during treatment discussion with fertility education</li> <li>Standard patient education sessions (e.g. Oncology Class) includes section on sexual health/function</li> <li>Reminders and re-introduction with each screening event</li> <li>Non-in-person modalities: video, pamphlets or other reading materials, website</li> </ul> </li> <li>II. Target population - Decisions and Examples:         <ul> <li>Age of inclusion (e.g. 12 years of age and older, 15 years of age and older)</li> <li>Treatment status: patients actively receiving therapy, survivors only</li> <li>Patient choice: Opt out vs. opt-in</li> </ul> </li> <li>III. Screening delivery - Decisions and Examples:         <ul> <li>Technology-based (e.g. through medical record, separate website) delivery (e.g. tablet/phone in clinic, text, email, mobile application)</li> <li>Paper-based delivery (e.g. in clinic, mailed)</li> <li>Non-English readers (translate tool, deliver verbally)</li> </ul> </li> <li>IV. Patient Privacy and Comfort - Decisions and Examples:         <ul> <li>Location of screening (e.g. at home, in clinic waiting room, in clinic private room)</li> <li>Timing of screening (e.g. thore, in clinic waiting room, in clinic private room)</li> <li>Timing of screening (e.g. before visit, during rooming of patient, while waiting for provider or other services, at end of visit)</li> <li>Minimizing parent/guardian presence during screening and conversations (asking parents to step out of room, providing separate space for screening or education, bringing patients back separately for screening)</li> <li>Consideration of patient choice in who addresses SF concerns (e.g., specific member of team, provider of same sex, etc.)</li> </ul></li></ol>	
		PROVIDER LEVEL	
MOTIVATING NEED/PROBLEM	CORE FUNCTIONS (Standardized)	FORMS (Tailored)	
Clinicians are	Increase	V. Provider Education - Decisions and Examples:	

	unaware of AYA oncology patients' SD needs and	provider awareness, knowledge and comfort of SD needs	Modality of education (e.g. written education such as handouts/powerpoints or interactive education such as computer modules/lectures/meetings)
how	how to address them		• Target provider population (e.g. physicians, advanced practice providers, nurses, medical assistants)
			Amount of education provided to each provider (e.g. universal materials, or graduated depending on role in clinic or role within sexual health care)
			Timing/frequency of provider education (e.g. single time point, regular interval re- education/reminders, performance-based education)
			VI. Screening Timing - Examples
		Consistently and periodically screen for SD needs using the PROMIS SexFS Brief	Initiation of screening (e.g. upon diagnosis, 1 month after diagnosis, at completion of therapy) Screening frequency: single time point, systematic interval (e.g., every 3 months or as frequently as patient comes) or patient tailored (e.g., frequency depends on diagnosis, patients' sexual history, etc.)
			VII. Consistency and Sustainability - Decisions and Examples
			Engaged personnel: established clinical champion(s), dedicated team, obtaining provider input/feedback on implementation
			Clear process for triggering screening (e.g. systematizing screening (automatic in medical record) or dedicated care manager/role)
			Provider reminders (e.g. in medical record manually or automatized via EHR functionality), on chemotherapy roadmaps)
			Provider feedback (e.g. regular updates on screening rates, notification of missed screening)
			VIII. Management of screening results - Decisions and Examples
			• Results storage modality: electronic (e.g. medical record, other database), paper (patient charts), or omit longitudinal storage)
		Consistently address SD needs once identified	Results/management storage and privacy: secure notes for minors vs. avoidance of documentation vs. normal documentation, limited vs. unrestricted access to results by medical providers
			Follow-up of screening results with patient: conversation with patient (in person, on phone, electronic), provide materials to patient (pamphlet/materials/website), automatic referral to specialists
			Responsible providers: existing oncology team, internal dedicated care manager or team, external specialist
			Management resources: evidence-based clinical decision-making tools, referral guides, established specialist partnerships

PROMIS SexFS Brief: National Institute of Health-developed Patient-Reported Outcomes Measurement Information System (PROMIS®) Sexual Function and Satisfaction (SexFS) Brief v2.0 SD: Sexual dysfunction 

233 Similarly, strategies for implementing the SD screening intervention, such as the plan for 234 provider education and support, will be tailored by site (Table 3). The intervention and 235 implementation menus were developed based on prior patient- and provider-engaged stages of 236 research. Further, the implementation menu was informed using established implementation 237 science strategies to target known barriers [19, 22, 39]. For example, to address lack of provider knowledge, implementation should include provider education and resources, which can take 238 239 several forms including education sessions, written education, clinical decision-making tools, or development of a dedicated expert team. Each strategy is intended to target study outcomes 240 including effectiveness, adoption, and implementation (acceptability, appropriateness). 241

242 Table 3. Implementation strategies

Component	Sub-component	Options	Outcome Target
Intervention design	Planning	-Selection of key partners (providers, patients, clinical leadership, RNs, MAs) in selecting flexible intervention components and implementation plan	Effectiveness Reach Adoption Implementation (Acceptability, feasibility)
	Iteration/Scale- up/Stage	-Optional stage	
Provider education	Modality	-Emails -Written education document -Presentations/meetings -Online modules	Effectiveness Adoption Implementation (acceptability, appropriateness)
	Content	-In depth vs. Overview	
	Who	-Only dedicated team members -All providers	
Provider Resources	Written	-Evidence-based clinical decision- making tools -Referral guides/work-up flow diagram	Effectiveness Reach Adoption Implementation (acceptability, appropriateness)
	Personnel	-Development of clinical team -Established specialist partnerships	
Reminders	Written	-EHR-based questionnaire automatic triggers -Dedicated team monitors at patient-level -EHR-Based (Best Practice Alerts, notes in chart) -Paper based/existing clinic documents (roadmaps, care pathways)	Reach Adoption Implementation (fidelity) (Sustainability)
	Verbal	-Clinical champions	

	Auditing/feedba	-Regular updates on screening ck rates					
243	EHR: electronic health record	-Notification of missed screening					
244	MA: medical assistant						
245 246	RN: Registered nurse						
240	Study Setting and Population						
248		ur clinical settings at two academic stand-alone children's					
249	hospitals: Children's Hospital C	olorado and Seattle Children's Hospital.					
250	Both patients and medie	al providers will be recruited for participation. Patients will be					
251	eligible for the study if they are	1) 15-24 years old at time of enrollment; 2) Have a current or					
252	prior history of cancer (Internat	onal Classification of Diseases for Oncology (ICD-O) with					
253	behavior code ≥2); 3) Cancer v	as diagnosed prior to age 18; and 4) Have received cancer-					
254	directed treatment (chemothera	py, immunotherapy, radiotherapy, or partial/total resection). Due					
255	to the nature of study procedur	es, patients will be excluded if they are 1) Unable to read/speak					
256	English; 2) Have insufficient co	gnitive function to complete study measures; 3) At end of life.					
257	Further, patients who participat	ed in intervention development will be excluded and participants					
258	who do not receive the interver	tion will not answer implementation-focused survey questions.					
259	Of note, while AYA-CCS both r	eceiving and having completed therapy will be included for					
260	secondary and exploratory outcomes, the primary outcome will evaluate effectiveness of the						
261	intervention among participants	who have completed therapy ("off-therapy"). The population for					
262	the primary outcome was desig	ned to mirror the inclusion criteria of our preceding qualitative					
263	study; the population was expanded to include patients currently on-therapy for secondary						
264	analyses based on subsequent	recommendations from providers [22, 40].					
265	Importantly, while the st	udy will only include patients who can read and speak English					
266	because the SexFS has only been validated in English, the clinical intervention will still be						
267	available to non-English speakers, through verbal screening delivery via an interpreter.						

All providers caring for patients at the study sites, including physicians, nurse

269 practitioners, physician assistants, registered nurses, and medical assistants, will be eligible for

- 270 participation.
- 271
- 272 Sample Size
- As a type 1 hybrid effectiveness-implementation trial, this study is powered to detect

274 preliminary effectiveness of the SD screening intervention. The primary outcome is the

275 proportion of off-therapy AYA-CCS participants reporting SD conversations with their providers

- (Table 4); on-therapy patients are included in this study as an exploratory aim but are not
- 277 included in minimal sample size based on power calculation. To detect a clinically relevant
- difference of 25% (5% pre-intervention vs. 30% post-intervention) in SD conversations with a
- 279 multivariable logistic regression assuming 20% of variability is explained by other predictors,
- 80% power, and alpha =.05, 86 participants will be required (43 pre- and 43 post-
- implementation of screening approach) [7, 19, 23].

#### 282Table 4. RE-AIM outcome measurement

RE-AIM Domain	Outcome/Measure(s)	Method
Reach	Proportion of eligible patients who completed SD screening	EHR abstraction
	Reason for missed screening (when relevant)	Surveys (providers)
	Representativeness: comparison of	EHR abstraction
	sociodemographic characteristics of patients receiving/not receiving intervention	
Effectiveness	Primary: off-therapy AYA-CCS-report of SD	Surveys (patients)
(primary	communication	Surveys (patients)
outcome)	Secondary:	
	All participant-report and on-therapy participant	
	report of SD communication	
	Patient satisfaction	
	Patient-report of needs being met	
	Exploratory:	EHR abstraction
	Incidence of documented SD	
	Incidence of referral to SD-related specialty	
	care	
Adoption	Provider-reported incidence of viewing SD	Surveys (providers)
	screening results	
	Provider-reported incidence of discussing SD results	Surveys (providers)

	Solicitation of description of adoption,	Interviews (providers)
	explanations for quantitative findings	
	Exploratory:	EHR abstraction
	Objective survey viewing data (e.g., EHR clicks)	
Implementation	Acceptability: Acceptability of Implementation	Surveys (patients, providers)
	Measure (AIM)	Interviews (providers)
	Appropriateness: Implementation	Surveys (patients, providers)
	Appropriateness Measure (IAM)	Interviews (providers)
		, , , , , , , , , , , , , , , , , , ,
	Feasibility: Feasibility of Intervention Measure	Surveys (patients, providers)
	(FIM)	Field notes (research team)
		Interviews (providers)
	Fidelity: extent to which each core function, and	Fidelity checklist (patient-report,
	site-adapted form, was followed	research team observation
		sampling)
	Adaptation: intervention and implementation	Observation, research/clinical
	adaptation details tracked following FRAME and	team communication
	FRAME-IS	
	Contextual factors: barriers, facilitators,	Open-ended survey questions
	recommendations	(patients, providers)
		Field notes (research team)
		Interviews (providers)
Maintenance	Continuation beyond study	
	· · ·	

- 283 AIM: Acceptability of Implementation Measure
- 284 AYA-CCS: Adolescent and young-adult aged childhood cancer survivors
- 285 EHR: electronic health record
- 286 FIM: Feasibility of Intervention Measure (FIM)
- 287 FRAME: Framework for Reporting Adaptations and Modifications-Expanded
- 288 FRAME-IS: Framework for Reporting Adaptations and Modifications to Evidence-based Implementation
- 289 Strategies
- 290 IAM: Implementation Appropriateness Measure
- 291 RE-AIM: Reach, Effectiveness, Adoption, Implementation and Maintenance
- 292 SD: Sexual dysfunction
- 293
- 294

This study will secondarily explore preliminary implementation outcomes through patient

implementation surveys administered in conjunction with assessment of effectiveness (n=43 off-

therapy AYA-CCS, with additional on-therapy participants). Provider implementation surveys will

- 297 be administered to consenting providers (anticipating an 80% response rate, approx. n=16-24),
- and semi-structured interviews with be completed with 10-15 providers directly involved in the
- 299 SD screening intervention. Additional brief interviews may be performed to capture experiences

300 of providers affected by, but not directly involved in, the intervention delivery (n=5-10). Because

interviews will be focused on experiences with the screening approach and barriers/facilitators,

we anticipate reaching thematic saturation with these sample sizes [41, 42].

303

#### 304 *Recruitment*

Recruitment will occur on a rolling basis during existing clinic visits or via phone within 4 305 weeks of the existing appointment. Sampling will be purposive to achieve variation across age 306 307 categories (age 15-19 and 20-24), patient treatment status (on-vs. off-therapy), and gender. In 308 the pre-intervention phase, patient participants will be given the opportunity to consent and 309 complete the survey at the same visit. However, post-intervention, consent and survey 310 completion will be delayed up to 4 weeks after the patient is "due" for the SD screening 311 intervention, to allow for buffer time for both screening and follow-up by the clinical team. Participation will be compensated with a gift card totaling \$10 pre-intervention (effectiveness 312 survey only) and \$20 post-intervention (effectiveness and implementation surveys). 313

314 Provider participants will be recruited for surveys via a variety of methods, including 315 email or in person requests. Enrollment of providers will occur at the end of the post-316 implementation study phase, with all eligible medical stakeholders approached for participation 317 in surveys. However, for sites that choose to have a limited number of providers responsible for 318 survey delivery and follow-up/management, only those responsible providers will receive 319 complete surveys, with other providers completing abbreviated surveys. Medical stakeholders 320 will receive \$10 gift card compensation for survey completion if the local site allows provider 321 incentives. A subset of providers will be recruited to complete qualitative, semistructured 322 interviews; recruitment will be purposeful to include provider participants with a range of survey 323 responses as well as proportional representation across roles and clinics. Interview participants will receive a \$40 gift card as compensation if the local site allows provider incentives. 324

325

326 Data Collection

327 RE-AIM outcome measurement for this study is detailed in Table 4 and below. Basic 328 demographic data, including gender identity, will be collected for all patient participants, and 329 details about providers' roles and experience will be collected for all provider participants.

330

331 Effectiveness

Effectiveness will be measured quantitatively via patient surveys (S2 Appendix). The 332 primary outcome is a patient-reported indicator that his/her provider has communicated with them 333 334 about SD. Secondary outcomes include patient satisfaction with SD communication [43] and 335 patient-report that an SD need was met. This study will also assess the feasibility of collecting EHR data in all eligible patients via retrospective chart review, specifically collecting exploratory 336 outcomes: 1) incidence of documented/detected SD; and 2) referral patterns to SD-related 337 338 specialty care (fertility team, urology, gynecology/oncology, sexual health clinic, endocrinology, 339 etc.).

#### 340 Implementation

Mixed methods will be used to assess RE-AIM outcomes in a multistage design, with 341 both explanatory sequential and convergent steps (Figure 2) [44]. Quantitative data collection 342 343 will include patient and provider participant surveys assessing reach, adoption, implementation (fidelity, feasibility, acceptability, appropriateness), as well as fidelity checklist observation by 344 the research team (S2 Appendix). EHR abstraction will be used to measure reach, adoption and 345 representativeness (Table 4). Qualitative data will include patient and provider responses to 346 347 open-ended survey questions, tracking of adaptations, observation by the research team, and nested explanatory sequential provider interviews further exploring implementation, barriers, 348 and facilitators. Interview guides will be informed by CFIR 2.0 and will be modified as needed 349 350 based on survey results; a preliminary guide is available in S2 Appendix. Adaptations to the SD 351 screening intervention and to the implementation plan for each site will be tracked using the

- 352 FRAME (Framework for Reporting Adaptations and Modifications-Expanded) and FRAME-IS
- 353 (Framework for Reporting Adaptations and Modifications to Evidence-based Implementation
- 354 Strategies), which are frameworks to characterize modifications to interventions (type of
- modification, reason for modification, timing, etc.) [45, 46].

# Figure 2. Mixed Methods evaluation of implementation of a sexual function screening intervention using patient and provider stakeholder input

358 <u>Study timeline</u>

359 Pre-intervention phase study recruitment began at Children's Hospital Colorado in

360 February 2023 and at Seattle Children's Hospital in December 2023, and is ongoing. The SD

361 screening intervention phase is expected to commence in Fall 2024 after completion of ongoing

- iterative refinement of the prototype.
- 363 <u>Analysis</u>
- 364
- 365 Effectiveness

366 Descriptive statistics (means, standard deviations, medians, ranges, frequencies,

367 percentages) will be computed for patient characteristics, overall and stratified by study period.

368 Differences in patient characteristics between study periods will be assessed using chi-squared

and t-tests (or appropriate bivariable tests based on variable type and distribution).

370 The primary analysis will compare the effect of the SD screening intervention on the

proportion of off-therapy AYA-CCS that self-report SD screening. We will use a multivariable

logistic regression model for the binary outcome of self-reported SD screening, controlling for

- 373 patient-level predictors identified a priori to be potential confounders (e.g., age, gender,
- 374 presence of SD concerns, endocrinopathies, clinic site, treatment status). Although there is
- 375 correlation due to the hierarchical structure of the data (patients within sites), due to the limited
- number of sites (<5), we will include a fixed effect for site rather than a random effect. Similar
- 377 exploratory analysis will occur for on-therapy participants. We will perform a subgroup analysis

by key variables (site, treatment status) using an interaction between the subgroup variable and the intervention period. The secondary outcome of whether a patient reported that their SD need was met will be analyzed similarly, overall and in the subgroup of those that indicated that they had a SD need, which will be assessed using an interaction with the SD need indicator and the pre-/post- indicator.

We will also use similar multivariable regression models adjusted for the same covariates to assess the effect of the intervention on secondary and exploratory outcomes: patient satisfaction, feasibility of collecting EHR data, and number of referral patterns. The specific link function for each regression model will be chosen appropriately based on the outcome type.

Goodness-of-fit tests and model-fitting diagnostics will be performed for proposed analyses to assess for influential points, outliers, and to evaluate alternative model specifications. All hypothesis tests will be two-sided with alpha=0.05, and p-values and confidence intervals will be reported. Statistical analyses will be conducted using R or SAS version 9.4 (SAS Institute Inc., Cary, N.C.).

393 Implementation

394 Because this is a pilot type 1 hybrid trial, analyses of implementation outcomes and contextual factors are descriptive, aiming to inform a future multicenter randomized hybrid trial. 395 396 Mixed methods integration will occur over several steps using connecting, building, merging and 397 embedding approaches (Figure 1) [44]. In merging steps, quantitative and qualitative survey data will be merged using a joint display [47]. Then, merged survey results will inform gualitative 398 data collection, including nested sampling and adaptation of the CFIR-informed interview guide. 399 400 Interviews will be analyzed using thematic content analysis, using both inductive and deductive 401 coding following CFIR 2.0 [48]. We will follow a team-based, inductive process in which two 402 team members will independently review and identify codes for the first several interview

transcripts. The research team will review respective code lists and transcripts, reconciling discrepancies in code definitions and applications. Iteration will continue during data collection until the research team is calibrated and a final codebook is established. Subsequently, a minimum of 20% of transcripts will be double-coded. ATLAS.ti 24 qualitative data management software will be used. Complete qualitative and quantitative results will then be summarized in a joint display to support development of implementation strategies to strengthen future testing and delivery of the screening approach [47].

#### 410 Quality assurance

This study aims to measure preliminary effectiveness of a flexible SD screening 411 412 intervention. Our sample size was selected to ensure ability to detect a clinically meaningful 413 improvement in SD communication. By assessing the intervention across multiple clinics in two 414 separate hospitals, the external validity of our findings will be strengthened; however, this is still 415 considered a pilot study and assessment across more sites with varied cultural settings will be 416 required in future studies. Further, we will use purposeful sampling to achieve maximum variation 417 across demographic groups and sites, though future research will be required to specifically evaluate effectiveness and implementation by subgroups (e.g., gender, race, sexual orientation), 418 419 and to evaluate the intervention in populations with a language preference other than English. In this type 1 hybrid trial, use of established implementation science frameworks (RE-420 421 AIM, CFIR 2.0, FRAME, FRAME-IS) strengthens our study design. Use of mixed methods to 422 assess implementation outcomes is expected to yield rich data to inform future implementation 423 and dissemination. Quantitative implementation data will use validated tools for provider partners (Acceptability of Implementation Measure (AIM), Feasibility of Intervention Measure 424 (FIM), Implementation Appropriateness Measure (IAM) increasing internal and external validity. 425 426 Patient-reported acceptability, feasibility, and appropriateness will be measured with study-427 specific, atient-focused questions following the AIM, FiM, and IAM format [49].

428 All study staff have undergone training to ensure fidelity across sites. Data will be 429 managed using REDCap and a data management plan will be used throughout the study to track data collection and ensure adherence to the study protocol [50]. Upon study completion, 430 data will be available with request. 431 432 To increase the credibility and trustworthiness of qualitative and mixed data, we will follow the Consolidated Criteria for Reporting Qualitative Research (COREQ), with particular 433 attention to the research team and reflexivity, study design, and analysis, and the Good 434 Reporting of Mixed Methods (GRAMM) criteria [51, 52]. Our team-based approach, described 435 436 above, will ensure analysis quality. Member checking may be implemented with a subset of participants. Use of mixed methods with multiple points of data merging, including use of 437 438 quantitative data to inform qualitative interviews, also improves validity. This protocol paper is intended to demonstrate neutrality; we will report deviations that 439

440 may occur throughout the study.

441

#### 442 <u>Ethics and dissemination</u>

443 This trial is approved by each sites' institutional review board (COMIRB 22-0709) and is 444 registered at ClinicalTrials.gov (NCT05524610). This project is supported by research funds from the NIH (K08 CA263192). Informed consent will be obtained from participants prior to 445 completing any aspect of the study. All data will be collected and stored through the password 446 447 protected and secure REDCap database; audio recordings and transcripts for qualitative 448 interviews will be stored in password protected files on the secure University of Colorado server. At each participating site, access to data will be restricted to approved study team members and 449 450 study-related files will be stored in password protected files. Data will be deidentified whenever 451 possible through the use of assigned study identification numbers. Data-sharing across sites will 452 not include personal health information.

453

Findings from this study will be disseminated through presentation at academic

- and professional conferences and in peer-reviewed journals. Deidentified research data will bemade publicly available when the study is completed and published.
- 456
- 457

#### 458 Discussion

Identification and treatment of SD in AYA CCS is an important and challenging guality of 459 life concern. This study will determine if our patient-centered SD screening approach and 460 implementation strategies are preliminarily effective and will describe implementation outcomes 461 462 and opportunities. By developing and testing the intervention while simultaneously exploring implementation outcomes and factors, this study will inform the development of a multisite 463 hybrid randomized trial testing clinical effectiveness and implementation strategies for the 464 screening approach. Future studies will also employ the screening approach in a multicenter SD 465 466 treatment intervention study, as well as evaluate use of the screening approach for other 467 sensitive AYA CCS issues. Ultimately, the goal of these endeavors is to improve detection, treatment and quality of life related to SD, and other unmet concerns, in AYA CCS. 468 469 470 **Declaration of Interests** The authors have declared that no competing interests exist. 471 472 473 **Funding Source** 474 This project is supported by research funds from the NIH (K08 CA263192). The sponsor does not have a role in study design, conduct or publication. 475 476 477 **Author Contributions** 

- 478 **Conceptualization**: Jenna Demedis, James L. Klosky, Brooke Dorsey Holliman, Pamela N.
- 479 Peterson, Christina Studts, Eric J. Chow
  - 23

- 480 Data curation: Jenna Demedis, Julia Reedy, Kristen Miller, Junxiao Hu
- 481 **Funding acquisition:** Jenna Demedis
- 482 Investigation: Jenna Demedis, Julia Reedy, Kristen Miller, Junxiao Hu, Brooke Dorsey
- 483 Holliman, Pamela N. Peterson, Christina Studts, Eric J. Chow
- 484 **Methodology**: Jenna Demedis, Julia Reedy, Junxiao Hu, James L. Klosky, Brooke Dorsey
- 485 Holliman, Pamela N. Peterson, Christina Studts, Eric J. Chow
- 486 Writing Original Draft: Jenna Demedis, Julia Reedy
- 487 Writing review & editing: Jenna Demedis, Julia Reedy, Kristen Miller, Junxiao Hu, James L.
- 488 Klosky, Brooke Dorsey Holliman, Pamela N. Peterson, Christina Studts, Eric J. Chow

489

### 490 **References**

Wettergren L, Kent EE, Mitchell SA, Zebrack B, Lynch CF, Rubenstein MB, et al. Cancer negatively
 impacts on sexual function in adolescents and young adults: The AYA HOPE study. Psychooncology.
 2017;26(10):1632-9.

Zebrack BJ, Foley S, Wittmann D, Leonard M. Sexual functioning in young adult survivors of
 childhood cancer. Psychooncology. 2010;19(8):814-22.

Bober SL, Zhou ES, Chen B, Manley PE, Kenney LB, Recklitis CJ. Sexual function in childhood
cancer survivors: a report from Project REACH. J Sex Med. 2013;10(8):2084-93.

4984.Haavisto A, Henriksson M, Heikkinen R, Puukko-Viertomies LR, Jahnukainen K. Sexual function in499male long-term survivors of childhood acute lymphoblastic leukemia. Cancer. 2016;122(14):2268-76.

5. Ritenour CW, Seidel KD, Leisenring W, Mertens AC, Wasilewski-Masker K, Shnorhavorian M, et
 al. Erectile Dysfunction in Male Survivors of Childhood Cancer-A Report From the Childhood Cancer
 Survivor Study. J Sex Med. 2016;13(6):945-54.

Ford JS, Kawashima T, Whitton J, Leisenring W, Laverdiere C, Stovall M, et al. Psychosexual
functioning among adult female survivors of childhood cancer: a report from the childhood cancer
survivor study. J Clin Oncol. 2014;32(28):3126-36.

Bjornard KL, Howell CR, Klosky JL, Chemaitilly W, Srivastava DK, Brinkman TM, et al.
 Psychosexual Functioning of Female Childhood Cancer Survivors: A Report From the St. Jude Lifetime
 Cohort Study. J Sex Med. 2020.

Sopfe J, Gupta A, Appiah LC, Chow EJ, Peterson PN. Sexual Dysfunction in Adolescent and Young
 Adult Survivors of Childhood Cancer: Presentation, Risk Factors, and Evaluation of an Underdiagnosed
 Late Effect: A Narrative Review. J Adolesc Young Adult Oncol. 2020.

- 512 9. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and 513 predictors. JAMA. 1999;281(6):537-44.
- 514 10. Sundberg KK, Lampic C, Arvidson J, Helstrom L, Wettergren L. Sexual function and experience
- among long-term survivors of childhood cancer. Eur J Cancer. 2011;47(3):397-403.

516 11. Acquati C, Zebrack BJ, Faul AC, Embry L, Aguilar C, Block R, et al. Sexual functioning among 517 young adult cancer patients: A 2-year longitudinal study. Cancer. 2018;124(2):398-405. 518 Carpentier MY, Fortenberry JD. Romantic and sexual relationships, body image, and fertility in 12. 519 adolescent and young adult testicular cancer survivors: a review of the literature. J Adolesc Health. 520 2010;47(2):115-25. 521 13. Children's Oncology Group. Long-Term Follow Up Guidelines for Survivors of Childhood, 522 Adolescent and Young Adult Cancer, Version 5.0 Monrovia, CA: Children's Oncology Group: Children's 523 Oncology Group; 2018 [updated October. Available from: www.survivorshipguidelines.org. 524 Canada AL, Schover LR, Li Y. A pilot intervention to enhance psychosexual development in 14. 525 adolescents and young adults with cancer. Pediatr Blood Cancer. 2007;49(6):824-8. 526 15. Bober SL, Recklitis CJ, Michaud AL, Wright AA. Improvement in sexual function after ovarian 527 cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer. Cancer. 528 2018;124(1):176-82. 529 16. Frederick NN, Recklitis CJ, Blackmon JE, Bober S. Sexual Dysfunction in Young Adult Survivors of 530 Childhood Cancer. Pediatr Blood Cancer. 2016;63(9):1622-8. 531 Krouwel EM, Albers LF, Nicolai MPJ, Putter H, Osanto S, Pelger RCM, et al. Discussing Sexual 17. 532 Health in the Medical Oncologist's Practice: Exploring Current Practice and Challenges. J Cancer Educ. 533 2019. 534 18. Park ER, Bober SL, Campbell EG, Recklitis CJ, Kutner JS, Diller L. General internist communication 535 about sexual function with cancer survivors. J Gen Intern Med. 2009;24 Suppl 2:S407-11. 536 Sopfe J, Marsh R, Frederick NN, Klosky JL, Chow EJ, Dorsey Holliman B, et al. Adolescent and 19. young adult childhood cancer survivors' preferences for screening and education of sexual function. 537 538 Pediatr Blood Cancer. 2021:e29229. 539 20. Frederick NN, Bingen K, Bober SL, Cherven B, Xu X, Quinn GP, et al. Pediatric oncology clinician 540 communication about sexual health with adolescents and young adults: A report from the children's 541 oncology group. Cancer Med. 2021;10(15):5110-9. 542 Frederick NN, Campbell K, Kenney LB, Moss K, Speckhart A, Bober SL. Barriers and facilitators to 21. 543 sexual and reproductive health communication between pediatric oncology clinicians and adolescent 544 and young adult patients: The clinician perspective. Pediatr Blood Cancer. 2018;65(8):e27087. 545 22. Demedis J, Reedy J, Chow EJ, Dorsey Holliman B, Peterson PN, Studts CR. Provider perspectives 546 and recommendations on standardized sexual function screening intervention in adolescent/young 547 adult oncology patients. Pediatr Blood Cancer. 2024:e30872. 548 23. Frederick NN, Revette A, Michaud A, Bober SL. A qualitative study of sexual and reproductive 549 health communication with adolescent and young adult oncology patients. Pediatr Blood Cancer. 550 2019:e27673. 551 24. Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, et al. Survivorship, 552 Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 553 2017;15(9):1140-63. 554 25. Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, et al. Interventions to Address 555 Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline 556 Adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36(5):492-511. 557 Coccia PF, Pappo AS, Beaupin L, Borges VF, Borinstein SC, Chugh R, et al. Adolescent and Young 26. 558 Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 559 2018;16(1):66-97. 560 27. Sopfe J, Marsh R, Ziniel SI, Klosky JL, Chow EJ, Dorsey Holliman B, et al. Evaluation of the v2.0 561 Brief Profiles for Sexual Function and Satisfaction PROMIS in Adolescent and Young Adult Childhood

562 Cancer Survivors. J Adolesc Young Adult Oncol. 2020.

Flynn KE, Reeve BB, Lin L, Cyranowski JM, Bruner DW, Weinfurt KP. Construct validity of the

Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for

PROMIS(R) sexual function and satisfaction measures in patients with cancer. Health Qual Life

563

564

565

566

28.

29.

Outcomes. 2013:11:40.

567 implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm 568 Policy Ment Health. 2011;38(2):65-76. Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM Planning and 569 30. 570 Evaluation Framework: Adapting to New Science and Practice With a 20-Year Review. Front Public 571 Health. 2019;7:64. 572 31. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation 573 of health services research findings into practice: a consolidated framework for advancing 574 implementation science. Implement Sci. 2009;4:50. 575 32. Damschroder LJ, Reardon CM, AuYoung M, Moin T, Datta SK, Sparks JB, et al. Implementation 576 findings from a hybrid III implementation-effectiveness trial of the Diabetes Prevention Program (DPP) in 577 the Veterans Health Administration (VHA). Implement Sci. 2017;12(1):94. 578 33. Arrossi S, Paolino M, Orellana L, Thouyaret L, Kohler RE, Viswanath K. Mixed-methods approach 579 to evaluate an mHealth intervention to increase adherence to triage of human papillomavirus-positive 580 women who have performed self-collection (the ATICA study): study protocol for a hybrid type I cluster 581 randomized effectiveness-implementation trial. Trials. 2019;20(1):148. 582 34. King DK, Shoup JA, Raebel MA, Anderson CB, Wagner NM, Ritzwoller DP, et al. Planning for 583 Implementation Success Using RE-AIM and CFIR Frameworks: A Qualitative Study. Front Public Health. 584 2020;8:59. 585 35. Moullin JC, Dickson KS, Stadnick NA, Albers B, Nilsen P, Broder-Fingert S, et al. Ten 586 recommendations for using implementation frameworks in research and practice. Implement Sci 587 Commun. 2020;1:42. 588 Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated 36. 589 Framework for Implementation Research based on user feedback. Implement Sci. 2022;17(1):75. 590 37. Perez Jolles M, Lengnick-Hall R, Mittman BS. Core Functions and Forms of Complex Health 591 Interventions: a Patient-Centered Medical Home Illustration. J Gen Intern Med. 2019;34(6):1032-8. 592 38. Esmail LC, Barasky R, Mittman BS, Hickam DH. Improving Comparative Effectiveness Research of Complex Health Interventions: Standards from the Patient-Centered Outcomes Research Institute 593 594 (PCORI). J Gen Intern Med. 2020;35(Suppl 2):875-81. 595 39. Powell BJ, McMillen JC, Proctor EK, Carpenter CR, Griffey RT, Bunger AC, et al. A compilation of 596 strategies for implementing clinical innovations in health and mental health. Med Care Res Rev. 597 2012;69(2):123-57. 598 40. Sopfe J, Marsh R, Appiah LC, Klosky JL, Peterson PN, DorseyHolliman B. Evaluating sexual 599 function in adolescent and young adult childhood cancer survivors. Journal of Clinical Oncology. 600 2020;38(15 suppl):e24180-e. 601 41. Guest G, Bunce A, Johnson L. How Many Interviews Are Enough?: An Experiment with Data 602 Saturation and Variability. Field Methods. 2006;18(1):59-82. 603 42. Faulkner L. Beyond the five-user assumption: benefits of increased sample sizes in usability 604 testing. Behav Res Methods Instrum Comput. 2003;35(3):379-83. 605 43. Olagunju TO, Liu Y, Liang LJ, Stomber JM, Griggs JJ, Ganz PA, et al. Disparities in the survivorship 606 experience among Latina survivors of breast cancer. Cancer. 2018;124(11):2373-80. 607 44. Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods designs-principles 608 and practices. Health Serv Res. 2013;48(6 Pt 2):2134-56. 609 45. Wiltsey Stirman S, Baumann AA, Miller CJ. The FRAME: an expanded framework for reporting 610 adaptations and modifications to evidence-based interventions. Implement Sci. 2019;14(1):58. 26

- 46. Miller CJ, Barnett ML, Baumann AA, Gutner CA, Wiltsey-Stirman S. The FRAME-IS: a framework
- 612 for documenting modifications to implementation strategies in healthcare. Implement Sci.
- 613 2021;16(1):36.
- 614 47. Guetterman TC, Fetters MD, Creswell JW. Integrating Quantitative and Qualitative Results in
- Health Science Mixed Methods Research Through Joint Displays. Ann Fam Med. 2015;13(6):554-61.
- 48. Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: Implications for
   conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398-405.
- 49. Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017;12(1):108.
- 620 50. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture 621 (REDCap)--a metadata-driven methodology and workflow process for providing translational research
- 622 informatics support. J Biomed Inform. 2009;42(2):377-81.
- 51. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a
- 624 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57.
- 625 52. O'Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services
- 626 research. J Health Serv Res Policy. 2008;13(2):92-8.
- 627

# 628 Supporting information captions

- 629 S1. Study Protocol: Aims 2-3 of this protocol represent the described clinical trial. Aim 1
- 630 represents a separate intervention adaptation phase.
- 631
- 632 S2. Study Appendix: Example participant surveys and interview guides
- 633
- 634 S3. Model consent forms
- 635
- 636 S4. SPIRIT Checklist

	Recruitment and Allocation	Post- allocation	Closeout
TIMEPOINT	0	0-4 weeks	4-8 weeks
ENROLLMENT:			
Eligibility screen	х		
Study presentation	х		
Informed consent		Х	
Allocation	х		
INTERVENTIONS:			
Pre-Intervention Arm	N/A (Pre- Intervention)		
Post-Intervention Arm	х		
A SSESSMENTS:			
Patient-reported demographics		х	
Effectiveness Survey		х	
Implementation Survey		X (Post-Int. Arm only)	
EHR Data Abstraction	2 and		х

EHR: Electronic Health Record

# Figure 1 SPIRIT Schedule




Figure 2 Mixed Methods